Pre-order Enquiry
Request Free Sample
Global Non-Insulin Therapies for Diabetes Market Size, Status and Forecast 2021-2027
SKU ID : QYR-19329888 | Publishing Date : 13-Oct-2021 | No. of pages : 129
Detailed TOC of Global Non-Insulin Therapies for Diabetes Market Size, Status and Forecast 2021-2027
1 Report Overview1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Alpha-glucosidase Inhibitors
1.2.3 Amylin Agonists
1.2.4 Biguanides
1.2.5 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
1.2.6 Glinides / Meglitinides
1.2.7 GLP-1 Analogs / GLP-1 Agonists
1.2.8 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
1.2.9 Sulfonylureas
1.2.10 Thiazolidinediones
1.2.11 Others
1.3 Market by Application
1.3.1 Global Non-Insulin Therapies for Diabetes Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Monitoring
1.3.3 Diagnosis
1.3.4 Treatment
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Non-Insulin Therapies for Diabetes Market Perspective (2016-2027)
2.2 Non-Insulin Therapies for Diabetes Growth Trends by Regions
2.2.1 Non-Insulin Therapies for Diabetes Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Non-Insulin Therapies for Diabetes Historic Market Share by Regions (2016-2021)
2.2.3 Non-Insulin Therapies for Diabetes Forecasted Market Size by Regions (2022-2027)
2.3 Non-Insulin Therapies for Diabetes Industry Dynamic
2.3.1 Non-Insulin Therapies for Diabetes Market Trends
2.3.2 Non-Insulin Therapies for Diabetes Market Drivers
2.3.3 Non-Insulin Therapies for Diabetes Market Challenges
2.3.4 Non-Insulin Therapies for Diabetes Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Insulin Therapies for Diabetes Players by Revenue
3.1.1 Global Top Non-Insulin Therapies for Diabetes Players by Revenue (2016-2021)
3.1.2 Global Non-Insulin Therapies for Diabetes Revenue Market Share by Players (2016-2021)
3.2 Global Non-Insulin Therapies for Diabetes Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Non-Insulin Therapies for Diabetes Revenue
3.4 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio
3.4.1 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Insulin Therapies for Diabetes Revenue in 2020
3.5 Non-Insulin Therapies for Diabetes Key Players Head office and Area Served
3.6 Key Players Non-Insulin Therapies for Diabetes Product Solution and Service
3.7 Date of Enter into Non-Insulin Therapies for Diabetes Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Insulin Therapies for Diabetes Breakdown Data by Type
4.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Type (2016-2021)
4.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Type (2022-2027)
5 Non-Insulin Therapies for Diabetes Breakdown Data by Application
5.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Application (2016-2021)
5.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Non-Insulin Therapies for Diabetes Market Size (2016-2027)
6.2 North America Non-Insulin Therapies for Diabetes Market Size by Type
6.2.1 North America Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021)
6.2.2 North America Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027)
6.2.3 North America Non-Insulin Therapies for Diabetes Market Size by Type (2016-2027)
6.3 North America Non-Insulin Therapies for Diabetes Market Size by Application
6.3.1 North America Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021)
6.3.2 North America Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027)
6.3.3 North America Non-Insulin Therapies for Diabetes Market Size by Application (2016-2027)
6.4 North America Non-Insulin Therapies for Diabetes Market Size by Country
6.4.1 North America Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021)
6.4.2 North America Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Non-Insulin Therapies for Diabetes Market Size (2016-2027)
7.2 Europe Non-Insulin Therapies for Diabetes Market Size by Type
7.2.1 Europe Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021)
7.2.2 Europe Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027)
7.2.3 Europe Non-Insulin Therapies for Diabetes Market Size by Type (2016-2027)
7.3 Europe Non-Insulin Therapies for Diabetes Market Size by Application
7.3.1 Europe Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021)
7.3.2 Europe Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027)
7.3.3 Europe Non-Insulin Therapies for Diabetes Market Size by Application (2016-2027)
7.4 Europe Non-Insulin Therapies for Diabetes Market Size by Country
7.4.1 Europe Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021)
7.4.2 Europe Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size (2016-2027)
8.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type
8.2.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2016-2027)
8.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application
8.3.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2016-2027)
8.4 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region
8.4.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Non-Insulin Therapies for Diabetes Market Size (2016-2027)
9.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Type
9.2.1 Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021)
9.2.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027)
9.2.3 Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2016-2027)
9.3 Latin America Non-Insulin Therapies for Diabetes Market Size by Application
9.3.1 Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021)
9.3.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027)
9.3.3 Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2016-2027)
9.4 Latin America Non-Insulin Therapies for Diabetes Market Size by Country
9.4.1 Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021)
9.4.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size (2016-2027)
10.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type
10.2.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type (2016-2027)
10.3 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application
10.3.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application (2016-2027)
10.4 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country
10.4.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Non-Insulin Therapies for Diabetes Introduction
11.1.4 GSK Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.1.5 GSK Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Introduction
11.2.4 Eli Lilly Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.2.5 Eli Lilly Recent Development
11.3 Sumitomo Dainippon Pharma
11.3.1 Sumitomo Dainippon Pharma Company Details
11.3.2 Sumitomo Dainippon Pharma Business Overview
11.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Introduction
11.3.4 Sumitomo Dainippon Pharma Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.3.5 Sumitomo Dainippon Pharma Recent Development
11.4 Intarcia Therapeutics
11.4.1 Intarcia Therapeutics Company Details
11.4.2 Intarcia Therapeutics Business Overview
11.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Introduction
11.4.4 Intarcia Therapeutics Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.4.5 Intarcia Therapeutics Recent Development
11.5 Servier
11.5.1 Servier Company Details
11.5.2 Servier Business Overview
11.5.3 Servier Non-Insulin Therapies for Diabetes Introduction
11.5.4 Servier Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.5.5 Servier Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Non-Insulin Therapies for Diabetes Introduction
11.6.4 Pfizer Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.6.5 Pfizer Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Non-Insulin Therapies for Diabetes Introduction
11.7.4 Merck Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.7.5 Merck Recent Development
11.8 Dong-A Pharmaceutical
11.8.1 Dong-A Pharmaceutical Company Details
11.8.2 Dong-A Pharmaceutical Business Overview
11.8.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Introduction
11.8.4 Dong-A Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.8.5 Dong-A Pharmaceutical Recent Development
11.9 Luye Pharma Group
11.9.1 Luye Pharma Group Company Details
11.9.2 Luye Pharma Group Business Overview
11.9.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Introduction
11.9.4 Luye Pharma Group Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.9.5 Luye Pharma Group Recent Development
11.10 Eurofarma
11.10.1 Eurofarma Company Details
11.10.2 Eurofarma Business Overview
11.10.3 Eurofarma Non-Insulin Therapies for Diabetes Introduction
11.10.4 Eurofarma Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.10.5 Eurofarma Recent Development
11.11 Geropharm
11.11.1 Geropharm Company Details
11.11.2 Geropharm Business Overview
11.11.3 Geropharm Non-Insulin Therapies for Diabetes Introduction
11.11.4 Geropharm Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.11.5 Geropharm Recent Development
11.12 Alkem Labs
11.12.1 Alkem Labs Company Details
11.12.2 Alkem Labs Business Overview
11.12.3 Alkem Labs Non-Insulin Therapies for Diabetes Introduction
11.12.4 Alkem Labs Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.12.5 Alkem Labs Recent Development
11.13 SatRx
11.13.1 SatRx Company Details
11.13.2 SatRx Business Overview
11.13.3 SatRx Non-Insulin Therapies for Diabetes Introduction
11.13.4 SatRx Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.13.5 SatRx Recent Development
11.14 Jiangsu Hansoh Pharmaceutical
11.14.1 Jiangsu Hansoh Pharmaceutical Company Details
11.14.2 Jiangsu Hansoh Pharmaceutical Business Overview
11.14.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Introduction
11.14.4 Jiangsu Hansoh Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.14.5 Jiangsu Hansoh Pharmaceutical Recent Development
11.15 Novo Nordisk
11.15.1 Novo Nordisk Company Details
11.15.2 Novo Nordisk Business Overview
11.15.3 Novo Nordisk Non-Insulin Therapies for Diabetes Introduction
11.15.4 Novo Nordisk Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.15.5 Novo Nordisk Recent Development
11.16 Emisphere
11.16.1 Emisphere Company Details
11.16.2 Emisphere Business Overview
11.16.3 Emisphere Non-Insulin Therapies for Diabetes Introduction
11.16.4 Emisphere Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.16.5 Emisphere Recent Development
11.17 Uni-Bio Science Group
11.17.1 Uni-Bio Science Group Company Details
11.17.2 Uni-Bio Science Group Business Overview
11.17.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Introduction
11.17.4 Uni-Bio Science Group Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.17.5 Uni-Bio Science Group Recent Development
11.18 Takeda
11.18.1 Takeda Company Details
11.18.2 Takeda Business Overview
11.18.3 Takeda Non-Insulin Therapies for Diabetes Introduction
11.18.4 Takeda Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.18.5 Takeda Recent Development
11.18 3SBio
.1 3SBio Company Details
.2 3SBio Business Overview
.3 3SBio Non-Insulin Therapies for Diabetes Introduction
.4 3SBio Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
.5 3SBio Recent Development
11.20 Jiangsu Hengrui Medicine
11.20.1 Jiangsu Hengrui Medicine Company Details
11.20.2 Jiangsu Hengrui Medicine Business Overview
11.20.3 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Introduction
11.20.4 Jiangsu Hengrui Medicine Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.20.5 Jiangsu Hengrui Medicine Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Figures, Tables and Charts Available in Global Non-Insulin Therapies for Diabetes Market Size, Status and Forecast 2021-2027
List of TablesTable 1. Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Alpha-glucosidase Inhibitors
Table 3. Key Players of Amylin Agonists
Table 4. Key Players of Biguanides
Table 5. Key Players of Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Table 6. Key Players of Glinides / Meglitinides
Table 7. Key Players of GLP-1 Analogs / GLP-1 Agonists
Table 8. Key Players of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Table 9. Key Players of Sulfonylureas
Table 10. Key Players of Thiazolidinediones
Table 11. Key Players of Others
Table 12. Global Non-Insulin Therapies for Diabetes Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 13. Global Non-Insulin Therapies for Diabetes Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 14. Global Non-Insulin Therapies for Diabetes Market Size by Regions (2016-2021) & (US$ Million)
Table 15. Global Non-Insulin Therapies for Diabetes Market Share by Regions (2016-2021)
Table 16. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 17. Global Non-Insulin Therapies for Diabetes Market Share by Regions (2022-2027)
Table 18. Non-Insulin Therapies for Diabetes Market Trends
Table 19. Non-Insulin Therapies for Diabetes Market Drivers
Table 20. Non-Insulin Therapies for Diabetes Market Challenges
Table 21. Non-Insulin Therapies for Diabetes Market Restraints
Table 22. Global Non-Insulin Therapies for Diabetes Revenue by Players (2016-2021) & (US$ Million)
Table 23. Global Non-Insulin Therapies for Diabetes Market Share by Players (2016-2021)
Table 24. Global Top Non-Insulin Therapies for Diabetes Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Insulin Therapies for Diabetes as of 2020)
Table 25. Ranking of Global Top Non-Insulin Therapies for Diabetes Companies by Revenue (US$ Million) in 2020
Table 26. Global 5 Largest Players Market Share by Non-Insulin Therapies for Diabetes Revenue (CR5 and HHI) & (2016-2021)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Non-Insulin Therapies for Diabetes Product Solution and Service
Table 29. Date of Enter into Non-Insulin Therapies for Diabetes Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) (US$ Million)
Table 32. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2016-2021)
Table 33. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 34. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 35. Global Non-Insulin Therapies for Diabetes Market Size Share by Application (2016-2021) & (US$ Million)
Table 36. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Application (2016-2021)
Table 37. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 38. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 39. North America Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) (US$ Million)
Table 40. North America Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) & (US$ Million)
Table 41. North America Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) (US$ Million)
Table 42. North America Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) & (US$ Million)
Table 43. North America Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021) & (US$ Million)
Table 44. North America Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027) & (US$ Million)
Table 45. Europe Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) (US$ Million)
Table 46. Europe Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) & (US$ Million)
Table 47. Europe Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) (US$ Million)
Table 48. Europe Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) & (US$ Million)
Table 49. Europe Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021) & (US$ Million)
Table 50. Europe Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) (US$ Million)
Table 52. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) & (US$ Million)
Table 53. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) (US$ Million)
Table 54. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) & (US$ Million)
Table 55. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2016-2021) & (US$ Million)
Table 56. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2022-2027) & (US$ Million)
Table 57. Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) (US$ Million)
Table 58. Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) & (US$ Million)
Table 59. Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) (US$ Million)
Table 60. Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) & (US$ Million)
Table 61. Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021) & (US$ Million)
Table 62. Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) (US$ Million)
Table 64. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) & (US$ Million)
Table 65. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) (US$ Million)
Table 66. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) & (US$ Million)
Table 67. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021) & (US$ Million)
Table 68. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027) & (US$ Million)
Table 69. GSK Company Details
Table 70. GSK Business Overview
Table 71. GSK Non-Insulin Therapies for Diabetes Product
Table 72. GSK Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 73. GSK Recent Development
Table 74. Eli Lilly Company Details
Table 75. Eli Lilly Business Overview
Table 76. Eli Lilly Non-Insulin Therapies for Diabetes Product
Table 77. Eli Lilly Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 78. Eli Lilly Recent Development
Table 79. Sumitomo Dainippon Pharma Company Details
Table 80. Sumitomo Dainippon Pharma Business Overview
Table 81. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product
Table 82. Sumitomo Dainippon Pharma Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 83. Sumitomo Dainippon Pharma Recent Development
Table 84. Intarcia Therapeutics Company Details
Table 85. Intarcia Therapeutics Business Overview
Table 86. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product
Table 87. Intarcia Therapeutics Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 88. Intarcia Therapeutics Recent Development
Table 89. Servier Company Details
Table 90. Servier Business Overview
Table 91. Servier Non-Insulin Therapies for Diabetes Product
Table 92. Servier Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 93. Servier Recent Development
Table 94. Pfizer Company Details
Table 95. Pfizer Business Overview
Table 96. Pfizer Non-Insulin Therapies for Diabetes Product
Table 97. Pfizer Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 98. Pfizer Recent Development
Table 99. Merck Company Details
Table 100. Merck Business Overview
Table 101. Merck Non-Insulin Therapies for Diabetes Product
Table 102. Merck Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 103. Merck Recent Development
Table 104. Dong-A Pharmaceutical Company Details
Table 105. Dong-A Pharmaceutical Business Overview
Table 106. Dong-A Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 107. Dong-A Pharmaceutical Recent Development
Table 108. Luye Pharma Group Company Details
Table 109. Luye Pharma Group Business Overview
Table 110. Luye Pharma Group Non-Insulin Therapies for Diabetes Product
Table 111. Luye Pharma Group Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 112. Luye Pharma Group Recent Development
Table 113. Eurofarma Company Details
Table 114. Eurofarma Business Overview
Table 115. Eurofarma Non-Insulin Therapies for Diabetes Product
Table 116. Eurofarma Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 117. Eurofarma Recent Development
Table 118. Geropharm Company Details
Table 119. Geropharm Business Overview
Table 120. Geropharm Non-Insulin Therapies for Diabetes Product
Table 121. Geropharm Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 122. Geropharm Recent Development
Table 123. Alkem Labs Company Details
Table 124. Alkem Labs Business Overview
Table 125. Alkem Labs Non-Insulin Therapies for Diabetes Product
Table 126. Alkem Labs Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 127. Alkem Labs Recent Development
Table 128. SatRx Company Details
Table 129. SatRx Business Overview
Table 130. SatRx Non-Insulin Therapies for Diabetes Product
Table 131. SatRx Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 132. SatRx Recent Development
Table 133. Jiangsu Hansoh Pharmaceutical Company Details
Table 134. Jiangsu Hansoh Pharmaceutical Business Overview
Table 135. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product
Table 136. Jiangsu Hansoh Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 137. Jiangsu Hansoh Pharmaceutical Recent Development
Table 138. Novo Nordisk Company Details
Table 139. Novo Nordisk Business Overview
Table 140. Novo Nordisk Non-Insulin Therapies for Diabetes Product
Table 141. Novo Nordisk Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 142. Novo Nordisk Recent Development
Table 143. Emisphere Company Details
Table 144. Emisphere Business Overview
Table 145. Emisphere Non-Insulin Therapies for Diabetes Product
Table 146. Emisphere Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 147. Emisphere Recent Development
Table 148. Uni-Bio Science Group Company Details
Table 149. Uni-Bio Science Group Business Overview
Table 150. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product
Table 151. Uni-Bio Science Group Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 152. Uni-Bio Science Group Recent Development
Table 153. Takeda Company Details
Table 154. Takeda Business Overview
Table 155. Takeda Non-Insulin Therapies for Diabetes Product
Table 156. Takeda Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 157. Takeda Recent Development
Table 158. 3SBio Company Details
Table 159. 3SBio Business Overview
Table 160. 3SBio Non-Insulin Therapies for Diabetes Product
Table 161. 3SBio Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 162. 3SBio Recent Development
Table 163. Jiangsu Hengrui Medicine Company Details
Table 164. Jiangsu Hengrui Medicine Business Overview
Table 165. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product
Table 166. Jiangsu Hengrui Medicine Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 167. Jiangsu Hengrui Medicine Recent Development
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Insulin Therapies for Diabetes Market Share by Type: 2020 VS 2027
Figure 2. Alpha-glucosidase Inhibitors Features
Figure 3. Amylin Agonists Features
Figure 4. Biguanides Features
Figure 5. Dipeptidyl Peptidase-4 (DPP4) Inhibitors Features
Figure 6. Glinides / Meglitinides Features
Figure 7. GLP-1 Analogs / GLP-1 Agonists Features
Figure 8. Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Features
Figure 9. Sulfonylureas Features
Figure 10. Thiazolidinediones Features
Figure 11. Others Features
Figure 12. Global Non-Insulin Therapies for Diabetes Market Share by Application: 2020 VS 2027
Figure 13. Monitoring Case Studies
Figure 14. Diagnosis Case Studies
Figure 15. Treatment Case Studies
Figure 16. Others Case Studies
Figure 17. Non-Insulin Therapies for Diabetes Report Years Considered
Figure 18. Global Non-Insulin Therapies for Diabetes Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 19. Global Non-Insulin Therapies for Diabetes Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 20. Global Non-Insulin Therapies for Diabetes Market Share by Regions: 2020 VS 2027
Figure 21. Global Non-Insulin Therapies for Diabetes Market Share by Regions (2022-2027)
Figure 22. Global Non-Insulin Therapies for Diabetes Market Share by Players in 2020
Figure 23. Global Top Non-Insulin Therapies for Diabetes Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Insulin Therapies for Diabetes as of 2020
Figure 24. The Top 10 and 5 Players Market Share by Non-Insulin Therapies for Diabetes Revenue in 2020
Figure 25. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2016-2021)
Figure 26. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2022-2027)
Figure 27. North America Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. North America Non-Insulin Therapies for Diabetes Market Share by Type (2016-2027)
Figure 29. North America Non-Insulin Therapies for Diabetes Market Share by Application (2016-2027)
Figure 30. North America Non-Insulin Therapies for Diabetes Market Share by Country (2016-2027)
Figure 31. United States Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Canada Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Europe Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Europe Non-Insulin Therapies for Diabetes Market Share by Type (2016-2027)
Figure 35. Europe Non-Insulin Therapies for Diabetes Market Share by Application (2016-2027)
Figure 36. Europe Non-Insulin Therapies for Diabetes Market Share by Country (2016-2027)
Figure 37. Germany Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. France Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. U.K. Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Italy Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Russia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Nordic Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Asia-Pacific Non-Insulin Therapies for Diabetes Market Share by Type (2016-2027)
Figure 45. Asia-Pacific Non-Insulin Therapies for Diabetes Market Share by Application (2016-2027)
Figure 46. Asia-Pacific Non-Insulin Therapies for Diabetes Market Share by Region (2016-2027)
Figure 47. China Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Japan Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. South Korea Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Southeast Asia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. India Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Australia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Latin America Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Latin America Non-Insulin Therapies for Diabetes Market Share by Type (2016-2027)
Figure 55. Latin America Non-Insulin Therapies for Diabetes Market Share by Application (2016-2027)
Figure 56. Latin America Non-Insulin Therapies for Diabetes Market Share by Country (2016-2027)
Figure 57. Mexico Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Brazil Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Middle East & Africa Non-Insulin Therapies for Diabetes Market Share by Type (2016-2027)
Figure 61. Middle East & Africa Non-Insulin Therapies for Diabetes Market Share by Application (2016-2027)
Figure 62. Middle East & Africa Non-Insulin Therapies for Diabetes Market Share by Country (2016-2027)
Figure 63. Turkey Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 64. Saudi Arabia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 65. UAE Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 66. GSK Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 67. Eli Lilly Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 68. Sumitomo Dainippon Pharma Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 69. Intarcia Therapeutics Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 70. Servier Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 71. Pfizer Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 72. Merck Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 73. Dong-A Pharmaceutical Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 74. Luye Pharma Group Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 75. Eurofarma Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 76. Geropharm Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 77. Alkem Labs Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 78. SatRx Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 79. Jiangsu Hansoh Pharmaceutical Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 80. Novo Nordisk Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 81. Emisphere Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 82. Uni-Bio Science Group Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 83. Takeda Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 84. 3SBio Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 85. Jiangsu Hengrui Medicine Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed
Keyplayers in Global Non-Insulin Therapies for Diabetes Market Size, Status and Forecast 2021-2027
GSKEli Lilly
Sumitomo Dainippon Pharma
Intarcia Therapeutics
Servier
Pfizer
Merck
Dong-A Pharmaceutical
Luye Pharma Group
Eurofarma
Geropharm
Alkem Labs
SatRx
Jiangsu Hansoh Pharmaceutical
Novo Nordisk
Emisphere
Uni-Bio Science Group
Takeda
3SBio
Jiangsu Hengrui Medicine
Request Sample
Request Discount
